ICLE 2022 | Developing an AvidCAR platform to improve T-cell activity
Michael Traxlmayr
• 1 Apr 2022
Michael Traxlmayr, PhD, University of Natural Resources and Life Sciences, Vienna, Austria, describes research on optimizing the efficacy of chimeric antigen receptors (CAR) T-cell therapies with a novel avidity-controlled CAR (AvidCAR) platform. AvidCARs are engineered with low-affinity antigen-binding domains, resulting in the need for bivalent antigen recognition for activation. Targeting cells expressing two specific antigens can subsequently increase the specificity and hence efficacy of potential T-cell therapies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
